Groupama Asset Managment Sells 32,272 Shares of Hologic, Inc. $HOLX

Key Points

• Groupama Asset Management has reduced its stake in Hologic, Inc. by 59.5%, selling 32,272 shares and leaving them with a total of 21,942 shares worth approximately $1,345,000.
• Recent analyst reports show varying ratings for Hologic, with Citigroup upgrading the stock to a "buy" and setting a price target of $80.00, while Wall Street Zen downgraded it from a "buy" to a "hold".
• Hologic's Q2 earnings exceeded expectations, reporting an EPS of $1.08 and revenue of $1.02 billion, with a year-over-year revenue increase of 1.2%.

Groupama Asset Managment decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 59.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,942 shares of the medical equipment provider's stock after selling 32,272 shares during the period. Groupama Asset Managment's holdings in Hologic were worth $1,345,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Farther Finance Advisors LLC lifted its position in shares of Hologic by 22.3% in the first quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider's stock worth $113,000 after buying an additional 335 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Hologic by 116.6% in the first quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider's stock worth $594,000 after buying an additional 5,172 shares during the last quarter. Brevan Howard Capital Management LP lifted its position in shares of Hologic by 85.5% in the fourth quarter. Brevan Howard Capital Management LP now owns 19,436 shares of the medical equipment provider's stock worth $1,401,000 after buying an additional 8,960 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in shares of Hologic by 1.7% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider's stock worth $1,980,000 after buying an additional 528 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky lifted its position in shares of Hologic by 4.5% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 17,945 shares of the medical equipment provider's stock worth $1,108,000 after buying an additional 767 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Stock Performance

HOLX traded up $1.09 on Friday, hitting $68.26. 1,545,907 shares of the stock traded hands, compared to its average volume of 1,851,908. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.39. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $15.18 billion, a PE ratio of 28.32, a P/E/G ratio of 2.48 and a beta of 0.49. The business has a fifty day moving average price of $65.90 and a two-hundred day moving average price of $62.42.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the company posted $1.06 earnings per share. The company's quarterly revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on HOLX shares. Argus raised Hologic from a "hold" rating to a "buy" rating and set a $80.00 price target for the company in a research report on Monday, August 18th. Raymond James Financial reissued an "outperform" rating and set a $71.00 price objective (down previously from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Stephens cut their price objective on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research report on Tuesday, May 13th. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $60.00 to $80.00 in a research report on Wednesday, July 9th. Finally, Wall Street Zen raised Hologic from a "hold" rating to a "buy" rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $78.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.